The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InFrench pharmaceutical group Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in an all-cash deal valued at $2.5 billion. Following the announcement, Day One's stock surged 65% on Friday morning, representing a nearly 70% premium over its previous closing price. The stock is currently trading at more than twice its price at the start of 2026, driven by the significant acquisition premium. Market analysts view the deal as a major validation of Day One's lead program, Ojemda (tovorafebin), a breakthrough treatment for pediatric low-grade glioma. This strategic move allows Servier to significantly bolster its global oncology portfolio and its pipeline for rare pediatric diseases. The transaction is slated to close in the second quarter of 2026, subject to customary regulatory approvals and shareholder consent.